NeuroDerm registers $50 million of ordinary stock for public offering

Bookrunners Jefferies and Cowen help fund clinical trials, research

By Devika Patel

Knoxville, Tenn., July 2 – NeuroDerm Ltd. will conduct a public sale of ordinary stock with a 30-day greenshoe, according to a Form F-1 filed Thursday with the Securities and Exchange Commission. The company has registered up to $50 million of stock.

Jefferies and Cowen and Co. are the bookrunning managers.

Proceeds will be used for clinical trials, research and development, working capital and general corporate purposes.

The clinical-stage pharmaceutical company is based in Rehovot, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.